Show simple item record

dc.contributor.authorChang, Hsien-Feng
dc.contributor.authorWu, Chang-Chieh
dc.contributor.authorSun, Chien-An
dc.contributor.authorChu, Chi-Ming
dc.contributor.authorLin, Fu-Gong
dc.contributor.authorHsieh, Jih-Fu
dc.contributor.authorHsu, Chih-Hsiung
dc.contributor.authorHuang, Chi-Hua
dc.contributor.authorYang, Tsan
dc.contributor.authorTsai, Yang-Ming
dc.contributor.authorKuan, Jen-Chun
dc.contributor.authorChou, Yu-Ching
dc.date.accessioned2021-07-19T23:46:10Z
dc.date.available2021-07-19T23:46:10Z
dc.date.issued2016
dc.identifier.issn1081-5589
dc.identifier.doi10.1136/jim-2016-000086
dc.identifier.urihttp://hdl.handle.net/10072/406146
dc.description.abstractAberrant DNA methylation plays a crucial role in cancer development; however, prospective evidence of an interaction between molecular biomarkers and cancer staging for predicting the prognosis of colorectal cancer (CRC) is still limited. We examined DNA methylation in tumors and adjacent normal tissues from patients who underwent CRC surgical resection, and evaluated the interaction between cancer staging (advanced vs local) and DNA methylation to predict the prognosis of CRC. We recruited 132 patients with CRC from Tri-Service General Hospital in Taiwan and used the candidate gene approach to select 3 tumor suppressor genes involved in carcinogenesis pathways. ORs and 95% CIs were computed using logistic regression analyses while adjusting for potential covariates. Advanced cancer stage was correlated with cancer recurrence (OR 7.22, 95% CI 2.82 to 18.45; p<0.001). In addition, after stratification by promoter methylation in 3 combined genes in the matched normal tissues, we observed a joint effect after adjusting for sex, age at surgery, and adjuvant chemotherapy, yielding a significant OR of 20.35 (95% CI 4.16 to 99.57; p<0.001). DNA methylation status would significantly increase the recurrence risk of CRC with a significant impact on joint effect between DNA methylation and clinical stage, particularly in matched normal tissues. This was attributed to molecular changes that could not be examined on the basis of clinical pathology. Our interaction results may serve as a reference marker for evaluating the risk of recurrence in future studies. ©
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherBMJ PUBLISHING GROUP
dc.relation.ispartofpagefrom1200
dc.relation.ispartofpageto1207
dc.relation.ispartofissue7
dc.relation.ispartofjournalJournal of Investigative Medicine
dc.relation.ispartofvolume64
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3202
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsMedicine, General & Internal
dc.subject.keywordsMedicine, Research & Experimental
dc.subject.keywordsGeneral & Internal Medicine
dc.titleClinical stage and risk of recurrence and mortality: interaction of DNA methylation factors in patients with colorectal cancer
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationChang, H-F; Wu, C-C; Sun, C-A; Chu, C-M; Lin, F-G; Hsieh, J-F; Hsu, C-H; Huang, C-H; Yang, T; Tsai, Y-M; Kuan, J-C; Chou, Y-C, Clinical stage and risk of recurrence and mortality: interaction of DNA methylation factors in patients with colorectal cancer, Journal of Investigative Medicine, 2016, 64 (7), pp. 1200-1207
dcterms.dateAccepted2016-05-22
dc.date.updated2021-07-19T23:43:14Z
gro.hasfulltextNo Full Text
gro.griffith.authorChu, Cordia M.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record